Screener
Gyre Therapeutics, Inc. GYRE Gyre — Sales & Marketing
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Revenues | $$29,734 | $$60,305 |
| Operating expenses: | ||
| Cost of revenues | 1,151 | 2,045 |
| Selling and marketing | 15,195 | 26,035 |
| Research and development | 8,351 | 16,442 |
| Research and development - related parties | — | — |
| General and administrative | 7,277 | 15,481 |
| Transaction costs | — | - |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — sales & marketing?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — sales & marketing of $0 in Q2 2026.
- What does gyre — sales & marketing mean?
- This represents the costs incurred by the segment to promote, advertise, and distribute its products or services to customers. It reflects the company's investment in market penetration, brand awareness, and customer acquisition strategies. High spending here is often necessary for growth but must be balanced against the resulting revenue impact.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — sales & marketing.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude